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INTRODUCTION
Multiple myeloma (MM) is a B-cell disorder character-
ized by the expansion of malignant plasma cells secre t i n g
monoclonal immunoglobulin. Several therapeutic a p p ro a c h e s
have been used to treat MM, including intensified high-dose
chemotherapy regimens followed by autologous or allo-
geneic stem cell transplantation (SCT). Although these
a p p roaches have resulted in an increased number of patients
achieving complete remissions and an improved survival rate,
most patients still relapse within a few years after transplan-
tation [1-5]. Relapse is presumed to result from the persis-
tence of small numbers of MM cells that cannot be detected
using standard staging criteria. Polymerase chain re a c t i o n
(PCR)-based studies have been used to determine the clinical
s i g n i ficance of minimal residual disease (MRD) after inten-
sive pro c e d u res [6-9]. These studies have shown persistence
of residual MM cells in the vast majority of patients, with the
possible exception of a fraction of patients undergoing allo-
geneic SCT [9,10]. It can be concluded from these studies
that even intensified chemotherapeutic approaches fail to
eradicate the malignant clone, and it has not been possible to
identify any subset of patients in whom qualitative PCR
assessment has shown prognostic significance. The develop-
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ABSTRACT
The majority of patients with multiple myeloma (MM) have persistence of minimal residual disease (MRD), as
d e t e rmined by polymerase chain reaction (PCR) detection of clonal immunoglobulin H (IgH) gene re a rr a n g e m e n t s .
As a result, PCR analysis has not provided clinically useful prognostic information in myeloma patients. Instead,
quantitative PCR approaches are re q u i red to predict patient outcomes and assess response to novel tre a t m e n t
strategies. We adapted real-time PCR technology to quantify myeloma cells using the IgH re a rrangement and then
assessed the utility of this approach in 29 patients with myeloma who had undergone autologous stem cell trans-
plantation. Because of the high cost of producing a specific re p o rting probe for each patient, H-chain V- re g i o n
f a m i l y – s p e c i fic consensus probes were used in association with allele-specific oligonucleotides for PCR amplific a-
t i o n . Because of the high frequency with which somatic hypermutation at the immunoglobulin locus occurs in MM,
a number of mismatches occurred between the patient sequences and the consensus probe. However, constru c t i o n
of a limited number of probes allowed real-time PCR with a sensitivity of 10–4 to 10– 5. To validate this method, we
extensively evaluated assay accuracy and re p ro d u c i b i l i t y. Results indicate that real-time PCR using consensus
p robes provides a feasible, accurate, and re p roducible method for evaluating MRD in MM and possibly in other dif-
f e rentiated B-cell malignancies, and one that is less expensive than the use of patient-specific probes. This tech-
nique is being used to assess tumor depletion after immunologic purging and changes in tumor burden in patients
u n d e rgoing stem cell transplantation and novel treatment approaches. 
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ment of an effective, accurate, and re p roducible quantitative
assay for MRD evaluation would likely re p resent an
e x t remely useful tool for identification of patients at high
risk for relapse. More o v e r, such a technique could be used
for comparative evaluation of purging pro c e d u res and rapid
assessment of the effectiveness of innovative treatments tar-
geting residual disease after SCT.
The most suitable clonal marker for MRD evaluation in
MM is the immunoglobulin H (IgH) re a rrangement [6-8,11].
This marker has been used extensively to examine the clinical
s i g n i ficance of MRD detection in a variety of B-cell malig-
nancies, including acute lymphocytic leukemia (ALL) [12,13],
c h ronic lymphocytic leukemia [14], mantle-cell lymphoma
[15,16], and MM [6-8,11]. Several studies have addre s s e d
quantitative analysis of MRD using the IgH re a rrangement in
MM, most often using end-point quantitation of PCR pro d-
ucts and limiting dilution methods [11,17-24]. No competi-
tive PCR studies have been published to date, primarily
because such studies would re q u i re construction of a patient-
s p e c i fic DNA competitor. The traditional quantitative and
semiquantitative PCR approaches of end-product DNA
analysis, limiting dilution strategies, and competitive PCR are
l a b o r-intensive, show a limited dynamic range, or give nonre-
p roducible results because extensive post-PCR processing is
re q u i red or because potential bias occurs during late postex-
ponential phases of PCR amplification [25-27].
R e c e n t l y, the introduction of TaqMan technology (PE
Biosystems, Foster City, CA) [28-30] and the development
of analytical thermal cyclers, such as the ABI Prism 7700
(PE Biosystems), have allowed development of extre m e l y
powerful systems for quantitation [25-27]. Detection of tar-
get DNA is based on the cleavage of fluorogenically labeled
probes by the 5′→3′ exonuclease activity of Taq DNA poly-
merase. These approaches have 2 main advantages. Fluores-
cence data are collected without post-PCR manipulation of
samples, and quantitative data are obtained by calculating
the number of cycles re q u i red for a given sample to enter
the exponential phase (threshold cycle, or Ct value), and not
by calculating the amount of end-point PCR product. 
Real-time PCR has been successfully employed for MRD
detection using several diff e rent tumor-specific transloca-
tions, including t(14:18) [31], t(9:22) [32], and t(8:21) [33]. In
addition, 2 small studies used the IgH re a rrangement as a
tumor cell marker [34,35]. In both studies, real-time PCR was
p e rf o rmed using patient-specific re p o rting probes derived
f rom the CDR3 region of IgH. These approaches are eff e c-
tive but extremely expensive when used for quantitative PCR
in large series of patients because of the high cost of pro d u c-
ing a re p o rter probe unique for each patient. An altern a t i v e
strategy involves the use of consensus probes derived fro m
the most conserved areas of the myeloma-specific IgH
re a rrangement; these areas can be used in association with
a l l e l e - s p e c i fic oligonucleotide (ASO) primers to obtain selec-
tive amplification of clonal IgH re a rr a n g e m e n t s .
In this study, we developed an effective method for IgH-
based real-time quantitative PCR using family-specific con-
sensus probes. We tested our method on a panel of 29 p a t i e n t s
with MM and demonstrated that a limited number of
m y e l o m a - s p e c i fic probes allowed quantitative analysis on the
e n t i re panel of patients. Quantitative PCR was successful on
both heavily and minimally infiltrated tumor samples. One
p a rticular problem using consensus probes in MM, as
opposed to other B-cell malignancies, is the high frequency of
somatic hypermutations that occur in patients with this dis-
ease [36]. There f o re, we assessed the impact of mismatch of
the consensus probe with the IgH sequence in MM. In addi-
tion, 2 diff e rent real-time PCR amplification strategies using
~300–base pair (bp) and ~120-bp amplicons were tested for
e ffectiveness and sensitivity, re s p e c t i v e l y. Extensive evaluation
of assay re p roducibility and accuracy was also perf o rm e d .
MATERIALS AND METHODS
Patients and Nucleic Acid Extraction
Bone marrow (BM) and peripheral blood (PB) samples
were obtained during standard diagnostic and staging proce-
dures and during stem cell mobilization for autografting. PB
and BM samples were also available from normal donors.
I n f o rmed consent was obtained from all patients, and the
study was approved by the Institutional Review Board for
Dana-Farber Cancer Institute. Initial IgH sequencing was
performed on samples displaying at least 2% tumor infiltra-
tion (range, 2% to 80%) as assessed by histopathology.
Mononuclear cells were separated by Ficoll-Hypaque den-
sity gradient centrifugation (Amersham Pharmacia Biotech
AB, Uppsala, Sweden). Genomic DNA was extracted as pre-
viously described [37]. Total RNA was obtained using Trizol
(Life Technologies, Grand Island, NY) according to manu-
f a c t u rer recommendations. Total and immunoglobulin-
specific complementary DNAs (cDNAs) were obtained as
previously described [6].
Amplification and Sequencing of the Tumor IgH 
Patient-specific IgH re a rrangements were amplified
starting from IgA- or IgG-specific cDNA according to the
p a t i e n t ’s known myeloma protein. In patients with light-
chain myeloma, total cDNA was used. The strategy used to
obtain the tumor-specific IgH is shown in Figure 1. Primers
and PCR conditions for IgH amplification have been
described [14,38]. Briefly, 2 µL cDNA was amplified using 3
sets of consensus forw a rd primers, 2 derived from frame-
work region (FR) 1 and 1 derived from the leader re g i o n ,
together with a J consensus region antisense primer [14]
(Figure 1). The reaction was carried out for 30 to 33 cycles
of denaturation at 94°C for 1 minute, annealing at 62°C for
30 seconds, and extension at 72°C for 30 seconds, with a
final extension of 10 minutes at 72°C. Samples were ampli-
fied by “hot start” PCR using Ampliwax 100 beads (PE
B i o s y s t e m s ) . PCR products were then analyzed by elec-
trophoresis on 2% agarose gels. When an apparently clonal
PCR product was observed, the sample of interest was
reamplified in large scale for direct sequencing of the tumor
IgH re a rrangement. Purification of PCR products, dire c t
sequencing reactions, and sequence analysis were performed
as described [15]. When direct sequencing did not allow the
reading of a clear sequence, PCR products were cloned with
the TA Cloning Kit (Invitrogen, San Diego, CA), using
blue-white colony selection according to the manufacturer’s
recommendations. A variable number of white-positive
colonies were grown by overnight shaking in Luria-Bertani
b roth containing 50 µg/mL ampicillin. Plasmid DNA was
purified using Wi z a rd Plus Minipreps resin and mini-
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columns (Promega, Madison, WI). A sequence repeated in
at least 3 diff e rent clones was considered to be the tumor
clone [14].
D evelopment of Quantitation Standar d s
Quantitation standards for the generation of standard
c u rves for real-time PCR were pre p a red by diluting plasmids
containing the patient-specific IgH re a rrangement. For 8 of
the 29 patients (28%), the cloned insert was already avail-
able, as it was obtained during IgH sequencing pro c e d u res. A
similar approach was used for patients whose samples were
sequenced after cloning [14]. Plasmid DNA concentrations
w e re evaluated by spectro p h o t o m e t ry, and 7 10-fold dilu-
tions in normal peripheral blood lymphocyte (PBL) DNA
w e re pre p a red, starting from 106 copies. These samples were
then stored at –20°C in single-use aliquots to avoid plasmid
deterioration or changes in concentration resulting fro m
repeated thawing and freezing of samples.
Design and Testing of ASO Primers
Reverse-ASO primers were designed from the CDR3 of
the tumor IgH and obtained from Gibco BRL (Gaithersburg ,
MD). The melting temperature of primers was chosen to be
as close as possible to 60°C (range, 58°C to 62°C). The speci-
ficity of reverse-ASO primers was tested in each patient by
PCR, using the same consensus forw a rd primer that allowed
successful IgH sequencing. Both the patient DNA sample and
a negative control sample consisting of DNA from norm a l
PBLs were amplified according to the following conditions:
1 µg target DNA was amplified in 50 µL final volume com-
prising PCR Buffer II (50 mmol/L KCl and 10 mmol/L
Tris/HCl, pH 8.3) (PE Biosystems), 2.5 mmol/L MgCl2, and
200 µmol/L of each dNTP (Ultrapure dNTP Set; Pharm ac i a ,
Lund, Sweden), adding 10 pmol of each primer and 1.5 u n i t s
A m p l i Taq DNA polymerase (PE Biosystems). Thirty cycles
of amplification were perf o rmed at 94°C for 30 seconds,
60°C for 30 seconds, and 72°C for 30 seconds, with a fin a l
extension of 10 minutes at 72°C. PCR products were then
run on 2% agarose gels. ASO primers were considered eff e c-
tive and specific if a band of the expected size was pre s e n t
exclusively on the patient DNA sample; specificity was con-
firmed by sequencing the product and comparing the re s u l t
to the sequence originally obtained.
Design of Consensus Probes for Real-Time PCR
Six H-chain V- region (VH) family–specific consensus
reverse probes (named L-VH1 to L-VH6) were initially
used. These were derived from the germline sequence of the
FR3 and designed for use in real-time PCR in childhood ALL
(Table 1) [39]. Because of the somatic hypermutations that
typically occur in MM [36] and other diff e rentiated B-cell
disorders, as well as different VH usage between ALL and
MM [40,41], 4 novel probes were required (named M-VH1
to M-VH4) (Table 1). These probes were designed by align-
ing a panel of 60 diff e rentiated B-cell malignancies, which
included sequences derived from MM patients and patients
with follicular lymphomas. Probes were designed from the
antisense DNA strand according to criteria re c o m m e n d e d
by PE Biosystems, synthesized by Oligo Factory (PE
Biosystems), and labeled at the 5′ end with the reporter dye
molecule 6-carboxy-fluorescein and at the 3′ end with the
quencher dye molecule 6-carboxy-tetramethyl-rh o d a m i n e .
In addition, the 3′ end of the probe was phosphorylated to
prevent extension of the probe during amplification.
Designing of F o r w a r d Primers
Two different real-time PCR assays were developed and
tested. The first reaction (FR1/ASO) employed the same
FR1-derived consensus forw a rd primers that allowed suc-
cessful IgH sequencing, together with reverse-ASO primers.
Amplicons from this reaction were approximately 300 bp
( F i g u re 2A). The alternative reaction (FR3/ASO) used
Figure 1. Schematic representation of the strategy used to amplify myeloma immunoglobulin H (IgH) sequences. Names and relative positions of primers used for
initial amplification are shown. Amplified IgH was directly sequenced and cloned to design allele-specific oligonucleotide (ASO) primers and provide quantitation
controls. Sequencing of clones allowed IgH sequencing in 8 additional patients in whom direct sequencing failed. CDR indicates complementarity-determining
region; D, diversity region; FR, framework region; J, joining region; L, leader region; V, variable region; VH.FD, variable region framework region 1 D series
primer; VH.FS, variable region framework region 1 S series primer; VH.LS, variable region leader sequence primer.
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Table 1. Probe Effectiveness and Mismatches Between Probes and Sequences
Probe and patient Sequence No. of Mismatches Success
Reverse-complemented ALL probes
L-VH1 GCACAGCCTACATGGAGCTGAGCAG
Patient #1-4 GCACAG TGTACATGGAGCTGAGCAG 2 Yes
Patient #1-1 GCACAGCCTA TATGGAGCTGAGCAG 2 Yes
Patient #1-3 GGACAGCCTACATGGA CCTGAGCAG 2 No
Patient #1-2 GCACAGC GTACATGGAG TTGA ACA C 4 No
L-VH2 GACCAACATGGACCCTGTGGACACAG
Patient #2-3 GACCAACATGGACCCTGTGGACACAG 0 Yes
Patient #2-1 GACCAACATGGACCCTG CGGAC TCAG 2 Yes
Patient #2-2 GACCAACATGGACCCT AGAGAC TCAG 4 No
L-VH3 GCCTGAGAGCCGAGGACACGG
Patient #3-12 GCCTGAGAGCCGAGGACACGG 0 Yes
Patient #3-3 GTCTGAGAGCCGAGGACACGG 1 Yes
Patient #3-1 GCCTGAGAGC TGAGGACACGG 1 Yes
Patient #3-5 GCCTGAGAG TCGAGGACACGG 1 Yes
Patient #3-7 GCCTGAGAGC TGAGGACACGG 1 Yes
Patient #3-9 GCCTGAGAG TCGAGGACACGG 1 Yes
Patient #3-10 GCCTGAGAGCCGAGGAC TCGG 1 Yes
Patient #3-13 GCCTGAGAG ACGAGGACACGG 1 Yes
Patient #3-11 GCCTGAGA CACGAGGACACGG 2 Yes
Patient #3-2 GCCTGAGAGC TGA AGACACGG 2 Yes
Patient #3-4 GCCTGAGA CC TGA AGACACGG 3 No
Patient #3-8 GCCTGA CA ACCGAGGACAC AG 3 No
Patient #3-8 GCCTGA AA ACCGAGGACAC AG 3 No
L-VH4 CAGTTCTCCCTGAAGCTGAGCTCTGTG
Patient #4-5 CAG GTCTCCCTGA GGCTGAGCTCTGTG 2 Yes
Patient #4-6 CAGTTCTCCCTGA GGCTGA CCTCTGTG 2 Yes
Patient #4-4 CAGTTCTCCCTGA GGCTGA ACTCTGTG 2 Yes
Patient #4-3 CAGTTCTCCCTGA GGCTG GCCTCTGTG 3 No
Patient #4-1 CAGTTCTCCCTGAAG GTG TCCTCTGTG 3 No
Patient #4-7 CAGTTCTC TGTGAA AATGAGCTCTGTG 4 No
Patient #4-2 CAGTTCTCCCTGAAGCTGA AGTCTGTG 2 No
L-VH5 CTACCTGCAGTGGAGCAGCCTGAAG
Patient #5-2 CTACCTGCAGTGGAGCAGCCTGAAG 0 Yes
Patient #5-1 CTAC TTGCAGTGGAGCAGCCTGAAG 1 Yes
L-VH6 CAGTTCTCCCTGCAGCTGAACTCTGTG
Reverse-complemented MM probes
M-VH1 CTACGCACAGAAGTTCCAGGGCAG
Patient #1-4 CTACGC GCAGAAGTTCCAGGGCAG 1 Yes
Patient #1-1 CTACGCACAG CAGTTCCAGGGCAG 1 Yes
Patient #1-3 CTACGCACAGAAGTTCCAGGGCAG 0 Yes
Patient #1-2 CTACGCACAGAAGTTCCAGGGCAG 0 Yes
M-VH2 AAGGACACCTCCAAAAACCAGGTGGT
Patient #2-3 AAGGACACCTCCAAAAACCAGGTGGT 0 Yes
Patient #2-1 AAGGACACCTCCAAAAACCA AGTGGT 1 Yes
Patient #2-2 AAGGACACCTCCAAAAACCAGGTGGT 0 Yes
M-VH3 TCCGCCAGGCTCCAGGGAAGGG
Patient #3-12 Not used — —
Patient #3-3 Not used — —
Patient #3-1 Not used — —
Patient #3-5 Not used — —
Patient #3-7 Not used — —
Patient #3-9 Not used — —
Patient #3-10 Not used — —
Patient #3-13 Not used — —
Patient #3-11 Not used — —
Patient #3-2 TCCGCCAGGCTCCAGG CAAGGG 1 Yes
Patient #3-4 TCCGCCAGGCTCCAGG CAAGGG 1 Yes
Patient #3-8 TCCGCCAGGCTCCAGGGAAGGG 0 Yes
Patient #3-6 TCCGCCAG CCTCCAGGGAAGGG 1 Yes
M-VH4º TCTGTGACCGCCGCAGACACG
Patient #4-5 TCTGTGACCGCCGCAGACACG 0 Yes
Patient #4-6 TCTGTGACCGCCGC GGACACG 1 Yes
Patient #4-4 TCTGTGACCGCCGC GGACACG 1 Yes
Patient #4-3 TCTGTGAC TGCCGCAGACACG 1 Yes
Patient #4-1 TCTGTGACCGCCGCAGACACG 0 Yes
Patient #4-7 TCTGTGACCGCCGC GGACACG 1 Yes
Patient #4-2 TCTGTGACCGC TGC GGACACG 2 Yes
M-VH5 Not designed
Patient #5-2 —
Patient #5-1 —
M-VH6 Not designed
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F i g u r e 2. Schematic representation and representative example of real-time polymerase chain reaction (PCR) strategies. A: FR1/ASO strategy. V gene
family–specific consensus primers from the FR1 were used with patient-specific primers from the CDR3 region for PCR amplification. Consensus probes were
designed from either the FR3 or the FR2 regions. Amplification plots and the derived standard curve of 6 10-fold plasmid dilutions from patient #4-1 (starting
from 106 plasmid copies) and of a normal PBL sample are shown. A positive signal was detected in the 102 copies dilution but not in the 101 copies dilution (sensi-
tivity, 10–3). B: FR3/ASO strategy. Patient-specific primers from the CDR2/FR3 region and CDR3 region were used for PCR amplification. Consensus probes
were derived from the FR3. Amplification plots and the derived standard curve of 6 10-fold plasmid dilutions (starting from 106 plasmid copies) and of a no-tem -
plate sample are shown. A positive signal was detected in the 101 copies dilution (sensitivity, 10–4). The consensus probe used in both samples illustrated was M-
VH4. CDR indicates complementarity-determining region; FR, framework region; Q, quencher; R, reporter dye.
Patient Specific PrimerConsensus Primer
FR2-Derived
Consensus Probe
FR3-Derived
Consensus Probe
FR3-Derived
Consensus Probe
Patient-Specific Primers
A
B
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patient-specific primers designed from the area immediately
5′ to the FR3-derived reported probe (Figure 2B). In some
of these cases, the primers were derived from the CDR2
instead of the FR3, depending on the different position of
family-specific reporting probes. Amplicons from this reac-
tion were approximately 100 to 150 bp.
Real-Time PCR Conditions and Quantitation of
Tu m o r -Specific IgH in Patient Samples
Real-time PCR was perf o rmed by amplifying 500 to
600 ng of target DNA in 50 µL volume using the Ta q M a n
PCR Core Reagent Kit reagents (PE Biosystems). The fol-
lowing conditions were used: 1× PCR Core Reagent Kit
B u ffer (which includes a third flu o rescent dye, 6-carboxy-X-
rhodamine, that acts as an internal re f e rence during data col-
lection); 2.5 mmol/L MgCl2; 200 µmol/L each of dAT P,
d C T P, and dGTP; 400 µmol/L dUTP, adding 10 pmol of each
primer; 5 pmol of re p o rting probe; 0.5 units of AmpErase
u r a c i l -N-glycosylase (PE Biosystems); and 1.25 units Ta q
Platinum DNA polymerase (Gibco BRL). After an incuba-
tion of 2 minutes at 50°C for optimal activity of AmpErase
and an incubation of 10 minutes at 95°C to activate Taq Plat-
inum, the following reaction was run: 4 cycles of denaturing
at 97°C for 15 seconds and annealing at 60°C to 62°C for
1 minute, followed by 38 cycles of denaturing at 95°C for
1 5 seconds and annealing at 60°C to 62°C for 1 minute.
Reactions were perf o rmed in an AbiPrism 7700 sequence
detector system (PE Biosystems). This device allows re a l -
time monitoring of PCR amplification through laser- m e d i-
ated analysis of sample fluorescence and analyzes spectral
data by plotting flu o rescence intensity versus cycle number. 
Primers and Probe and Real-Time PCR Conditions
for the Gl y c e r a l d e h yde-3-Phosphate Deh y d r oge n a s e
R e fe r ence Standard
The glyceraldehyde-3-phosphate dehydro g e n a s e
(GAPDH) locus [42] was chosen as the re f e rence standard
to normalize patient samples for DNA quality and quantity
[39]. Sequences of the GAPDH primers were as follows:
f o rw a rd primer (derived from the third intron of the gene),
CAAAGCTGGTGTGGGAGG; reverse primer (derived
f rom the fourth exon of the gene), CTCCTGGAAGAT G
G T G AT G G. The forw a rd primer was chosen from an
i n t ronic sequence that is absent in the GAPDH pseudo-
gene to avoid coamplification of this target. The probe for
the GAPDH real-time amplification was labeled with the
re p o rter dye 2,7-dimethoxy-4,5-dichloro - 6 - c a r b o x y -
f l u orescein (JOE) re p o rter molecule and had the following
sequence: 5′ J O E - C A A G C T T C C C G T T C T C A G C C-
TA M R A - 3′. Real-time PCR conditions for the GAPDH
real-time PCR were identical to those used for the IgH
re a rrangement, with the exception that only 1.5 pmol of
each primer was added to the reaction. Samples were ana-
lyzed in triplicate. A quantitation standard was generated
by cloning the PCR product obtained by amplification of
n o rmal PBL cells. Where indicated, the number of clonal
IgH copies for each patient sample was normalized to the
number of GAPDH copies. Mean GAPDH values were
calculated and used for sample normalization. Values were
then expressed as IgH copies/100,000 diploid genomes. If
estimated numbers of diploid genomes were lower than
1 × 1 04 or greater than 5 × 1 05, quantitative analysis was
repeated after appropriate dilution or concentration of
samples to ensure that optimal amounts of PCR-amplifia b l e
DNA were contained within each reaction tube, and also
to provide the greatest possible homogeneity of samples
used for real-time PCR.
Statistical Anal y s i s
The Wilcoxon rank sum test was used to assess the rela-
tionship between the number of mismatches and pro b e
effectiveness [43]. The κ statistic was computed to evaluate
the agreement between the 2 strategies tested (FR1/ASO
and FR3/ASO) [43]. This chance-corrected measure of
a g reement ranges up to 1 depending on the strength of
agreement. According to the guidelines of Landis and Koch
[44], a κ statistic between 0 and 0.4 denotes marginal agree-
ment; between 0.4 and 0.75, good agreement; and gre a t e r
than 0.75, excellent agreement. The re p roducibility of the
PCR reaction was evaluated by examining the agre e m e n t
between the log (base 10) of the mean number of IgH
copies at each run. The 95% confidence interval (CI) in the
difference in the log (base 10) of mean values at the 2 repli-
cates is re p o rted. Graphic pro c e d u res were used to assess
whether the variability between different runs on the same
patient sample increased with the number of IgH copies.
Similar descriptive pro c e d u res were used to evaluate the
within-run reproducibility of the PCR by comparing the log
number of IgH copies within each run.
RESULTS
Criteria of Eff e c t i v eness for Real-Time PCR
The aim of this study was to evaluate whether re a l - t i m e
PCR using consensus probes could successfully be employed
for quantitative evaluation of MRD in patients with MM.
Real-time PCR of a given patient re a rrangement was consid-
e red effective if the reaction could fulfill at least the follow-
ing 3 criteria. (1) The amplification showed a clear positive
signal in the dilution to which 10 plasmid copies were added.
Because the amount of genomic DNA added to each re a c-
tion contained approximately 105 genomes, a positive signal
in the 10–immunoglobulin copies dilution re p resented a sen-
sitivity of 10– 4. (2) No nonspecific PCR product was
o b s e rved when DNA from healthy donor PBL was amplifie d
by PCR. (3) The amplification of 7 10-fold dilutions of the
patient plasmid (starting from 106 copies) gave rise to a stan-
d a rd curve showing r > 0.98.
Real-Time PCR Using Germline Consensus Probes 
Real-time PCR was first attempted in 29 patients using
a panel of 6 FR3-derived consensus probes (1 for each VH
family) that had been designed in our laboratory for use in
patients with pre–B-cell ALL [39]. The sequences of these
consensus probes are shown in Table 1. Real-time PCR was
successful  using these probes  in  only  19 of  the 29
myeloma patients tested (66%) (Table 1). However, in all
patient samples in which real-time PCR was unsuccessful,
qualitative PCR was successful, as confirmed by sequencing
of the resulting PCR product. This suggests that the lack of
success with real-time PCR was due to failure of the probe
and not to lack of amplification. 
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Because there can be a high degree of somatic hyperm u-
tation of IgH in MM, as well as diff e rent VH usage between
MM and ALL [36,40,41], we analyzed whether the pro b e s
matched the sequences found in MM patients. As can be seen
in Table 1, comparison of the probe sequence with the
patient-derived MM sequences demonstrated variable mis-
matches. The IgH sequence was in germline configuration
at the region of the probe in only 3 cases. In the re m a i n i n g
26 patients, 4 mismatches were found in 3 patients, 3 mis-
matches in 5 patients, 2 mismatches in 9 patients, and 1 mis-
match in 9 patients. Mismatches were found throughout the
p robe sequence, but notably, in cases in which the pro b e
worked successfully, no mismatches occurred in the first
3 nucleotides of the probe. A statistically significant re l a t i o n-
ship was observed between probe failure and number of mis-
matches (P < .001). In the presence of 3 or 4 mismatches, the
p robes always failed, whereas if 1 or no mismatches were
p resent, real-time PCR was always successful. Nine patients
displayed 2 mismatches. Here the type and site of the mis-
match were relevant, depending on whether the mismatch
involved substitution of G/C (strong interaction) or A/T
(weak interaction). Real-time PCR was always effective if
2 weak interactions or 1 weak and 1 strong interaction were
lost (4 patients). In 5 patients, 2 strong interactions were lost;
p robe failure was observed in 2 of these patients, but eff e c t i v e
real-time PCR according to our criteria was observed in the
remaining 3 patients (although in 1 patient, the eff e c t i v e n e s s
of PCR was suboptimal in terms of maximal fluore s c e n c e
i n t e n s i t y). Of interest, in the 2 patient samples in which an
optimal amplification was observed despite the disruption of 2
s t rong interactions, no mismatches were present in the first 11
n u c l e otides of the consensus probe. In the remaining patients,
1 or both mismatches were located in the 5′ p o rtion of the
p robe. In addition, L-VH1, L-VH2, and L-VH4 probes were
most often ineffective, whereas L-VH3 and L-VH5 pro b e s
w e re effective in the majority of patients. No MM patients
using VH6 were available, and this family is rarely used in
MM [41]. However, this probe has proved to be effective in
other B-cell malignancies [39].
Designing and Testing Additional Probes 
for Real-Time PCR in MM P a t i e n t s
To increase the number of effective real-time amplifica-
tions in our patients, we screened a panel of 60 IgH
sequences that included all 29 of the MM sequences fro m
this study as well as sequences from 31 patients with non-
Hodgkin’s lymphoma. Three novel probes (named M-VH1,
M-VH2, and M-VH4) derived from the FR3 were designed
for the VH1, VH2, and VH4 families (see Table 1). These
p robes had 1 or no mismatches for all our MM patients
(with the exception of patient #4-2, for whom the probe had
2 mismatches in VH4 involving 1 weak and 1 strong inter-
action), as well as for the vast majority of lymphoma
patients. For the larger VH3 family, it was not possible to
design a single consensus probe for all patients, and there-
f o re we used 2 diff e rent consensus probes. L-VH3 was
employed successfully in 75% of patients, whereas for the
remaining 25% of patients, a novel FR2-derived pro b e
( M -VH3) was designed by aligning the VH3 sequences that
failed real-time PCR using L-VH3. All of our patients using
VH3 sequences matched at least 1 of the 2 VH3-derived
p robes (Table 1), and real-time PCR using these novel
p robes was successful in all 18 patients in whom it was
tested. This included 4 patients in whom M-VH1 was used;
3 patients in whom M-VH2 was used; 4 patients in whom
M-VH3 was used, including 3 patients (#3-4, #3-6, and #3-8)
in whom amplification with L-VH3 failed and 1 patient
( # 3 -2) in whom real-time PCR was effective but suboptimal
using this probe; and 7 patients in whom M-VH4 was used.
N o t a b l y, it was possible to determine whether the L-VH3
p robe would be successful based on comparison of the pro b e
sequence with the patient sequence; thus, probe eff e c t i v e n e s s
can be easily predicted on the basis of the number and quality
of mismatches. To determine whether these alternative pro b e s
p roduced comparable results for use in quantitation, we per-
f o rmed real-time PCR analysis using the FR1/ASO strategy
on samples from patient #3-5 using M-VH3 (no mismatches)
and L-VH3 (1 mismatch). Comparable results were obtained
using both probes. Similar results were obtained in patient #2-
3 using the M-VH2 and L-VH2 probes (data not shown).
FR1/ASO Versus FR3/ASO Strategies
Two strategies using diff e rent forw a rd primers were
tested on our panel of MM patients. The first strategy
(FR1/ASO) used the consensus FR1-derived primer used for
IgH sequencing. In patient samples in which IgH sequenc-
ing re q u i red primers derived from the leader region, a
patient-specific primer was designed from the FR1 (Figure
2A). This strategy produces a PCR product of approxim a t e l y
300 bp. Because shorter amplicons are considered more suit-
able for TaqMan-based approaches, we designed a second
s t r a t e g y, FR3/ASO, that used patient-specific primers
designed immediately 5′ to the reporter probe but involved
the use of shorter amplicons (Figure 2B). In the 3 patient
samples in which only the M-VH3 probe was successful,
this strategy could not be used, and therefore we performed
comparative analysis of the 2 strategies in the sequences
from all 26 patients in which both were feasible.
Table 2. Comparison Between the FR1/ASO and FR3/ASO Strategies (n = 26)
FR3/ASO
Medium Sensitivity High Sensitivity
Failure (>10 –3 and <10 –4) (>10 –4) Total
Failure 0 2 5 7
Medium Sensitivity (>10 –3 and <10 –4) 0 1 5 6
High Sensitivity (>10 –4) 0 0 13 13
Total 0 3 23 26
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The FR1/ASO strategy was effective in 19 of the
26 patients (73%) (Table 2). In the remaining 7 patients,
the reaction was insensitive, had an observed corre l a t i o n
c o e fficient less than 0.98, or both. More o v e r, in 6 of the
19 patients in whom it proved successful, a sensitivity of
only 10– 3 was observed. There f o re, this technique pro v e d
ineffective or was effective but with suboptimal sensitivity in
13 of the 26 patients (50%). In contrast, the FR3/ASO reac-
tion was effective in all 26 patients, and a sensitivity level of
10–4 or greater was obtained in 23 of 26 patients (88%). The
estimated κ statistic of 0.13 indicates marginal agre e m e n t
between the 2 strategies (P = .09). In the 12 patients for
whom the strategies did not agree, the FR3/ASO was more
sensitive (all of the cases that were failures with the
FR1/ASO strategy were detected by the FR3/ASO strategy,
and all of the cases that were detected with low sensitivity
w e re detected with high sensitivity). Thus, the combined
use of the FR1/ASO strategy in association with the FR2-
derived M-VH3 probe, as well as the FR3/ASO strategy
with other probes, allowed successful real-time PCR in
100% of patients. Sensitivity was 10– 4 or greater in 26 of
29 patients (90%), and 10– 3 in 3 of 29 (10%). In the 3 patients
whose samples had low sensitivity (#3-7, #3-10, and #2-1), a
second ASO primer was designed and the quantitation stan-
dard again cloned to exclude inappropriate primer annealing
or the presence of PCR inhibitors. However, despite these
changes, sensitivity did not improve. 
A possible limitation of using 2 diff e rent strategies is
that these 2 methodologies would produce noncomparable
results for quantification of tumor load in patient samples.
T h e re f o re, we used both methods in triplicate for quantita-
tion of tumor load in peripheral blood stem cell (PBSC)
collections obtained from 3 patients (#3-1, #4-3, and #5-1)
with MM. Although we observed comparable results in
multiple samples from 2 patients, in patient #3-1, re p e a t e d
rounds of amplifications consistently showed that quantita-
tive data obtained from the FR1/ASO were appro x i m a t e l y
0.5 log lower than those obtained with the FR3/ASO. We
reasoned that this could be due to less efficient amplific a-
tion of tumor sequences compared with plasmid sequences
because of an incomplete match between patient IgH and
consensus primer. There f o re, we perf o rmed real-time PCR
using a novel tumor-specific primer designed immediately
3′ to the sequence of the consensus FR1-derived primer.
Quantitative results obtained from the modified FR1/ASO
strategy were superimposable to those obtained with the
FR3/ASO strategy (data not shown). These data suggest
that quantitative analysis using the shorter amplicons is
m o re accurate to assess MRD.
Intra- and Interassay Repr o d u c i b i l i t y
Real-time PCR analysis was perf o rmed on 22 samples
obtained from 7 patients at diff e rent treatment phases in
their disease to evaluate assay reproducibility in both heavily
infiltrated tumor samples and samples displaying minimal
tumor contamination. Four DNA samples were from BM
obtained at diagnosis or after conventional chemotherapy,
16 were from unmanipulated PBSC collections, and 2 were
f rom PBSC samples that had undergone CD34+ s e l e c t i o n .
All these samples had PCR evidence of residual disease
when analyzed using our standard qualitative nested PCR
s t r a t e g y, which has a sensitivity of 10– 5 (data not shown).
Real-time PCR was performed on these samples in 2 differ-
ent amplifications, with 3 replicates generated for each
amplification (Figure 3A). On 3 samples, an additional
amplification was performed. Analysis of intra- and interas-
say re p roducibility was perf o rmed, and mean values and
standard deviations were calculated (Figure 3B). The log of
the mean number of IgH copies and the standard deviation
was computed for each sample. As shown in Figure 3C,
t h e re was good agreement between amplifications per-
formed on the same samples (r = 0.98). The mean difference
between the log of the mean number of IgH copies at the 2
amplifications was 0.07 (SE 0.05; 95% CI: –0.02 to 0.17). It
is interesting to note that the variability is largest between
1 log IgH copies and 2 log IgH copies (Figure 3D). Assess-
ment of the intrarun variability of a sample (ie, the variabil-
ity among triplicates) proved that there was good agreement
among the log number of IgH copies from the 3 re a c t i o n
wells (r > 0.98). Figure 3E illustrates the agreement between
wells 1 and 2; a similar relationship was observed between
wells 1 and 3 and between wells 2 and 3 (data not shown).
As seen before, variability did not increase with the log
number of IgH copies (Figure 3F). There f o re, we found
good correlation for quantification of IgH copy number
both within and between runs on the samples analyzed.
In samples with very low tumor burden, both positive and
negative amplifications were occasionally observed among the
6 replicates. In such a situation, a sample displaying no ampli-
fication was scored as 0 IgH copies. Real-time PCR was able
to quantify IgH re a rrangements in tumor samples ranging
f rom 5.9 × 1 04 IgH copies to as few as 4.5 IgH copies. Of
note, 1 of the CD34+ selected samples was repeatedly PCR
negative when assessed by real-time PCR yet was persistently
PCR positive when assessed by qualitative nested PCR. This
is in accordance with sensitivity data showing that re a l - t i m e
PCR is at least 1 log less sensitive than nested PCR. This
highlights the complementarity of perf o rming both qualita-
tive and quantitative PCR analysis. However, a semiquantita-
tive assessment of tumor is possible under these circ u m-
stances, as the tumor burden must be between the limits of
sensitivity of the 2 assays. 
Accuracy Evaluation
To validate that real-time PCR was able to pro v i d e
accurate quantitation of samples, we first performed dilution
experiments using the DHL-16 cell line, since we had
p re v iously characterized its IgH re a rrangement. Its IgH
rearrangement uses VH3, contains somatic hypermutation,
and has 1 mismatch for the VH3 probe used for quantita-
tion. Doubling dilutions into normal peripheral blood
mononuclear cells were made, quantitative PCR analysis
was performed (Figure 4A), and the IgH copy numbers were
c o rrected for the GAPDH copy number. The calculated
results were analyzed to determine whether this methodol-
ogy was capable of detecting 2-fold diff e rences in tumor
contamination, particularly when the amount of tumor con-
tamination was small (Figure 4B)—indeed, 2-fold diff e r-
ences could be distinguished easily. 
Next we evaluated whether data obtained from re a l -
time PCR were comparable to the expected number of
clonal re a rrangements in samples over a wide range of
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F i g u r e 3. A: Amplification plot of a representative example of reproducibility analysis. Triplicate amplifications of 4 samples from patient #3-1 are shown: BM at
diagnosis (red), unmanipulated PBSC I (blue), unmanipulated PBSC II (light blue), and CD34 selected pooled PBSC (yellow). All samples were tested in triplicate to
evaluate intra-assay reproducibility. B: Mean values and standard deviation for the same samples, amplified 6 times in 2 different rounds of amplification to evaluate
inter- and intra-assay reproducibility. C: Reproducibility of immunoglobulin H (IgH) copy number (log scale), showing agreement in results obtained on the same sam-
ple analyzed at different time points (r = 0.98). D: Reproducibility of IgH copy number (log scale) showing mean and standard deviation of results obtained on the same
sample analyzed at different time points. Most variability occurred between 1 and 2 log for IgH copy numbers. E: Reproducibility of IgH copy number (log scale) show-
ing intra-assay agreement within triplicates (r > 0.98). Shown is the agreement between well 1 and well 2. Similar results were obtained for well 2 versus well 3 and
well 1 versus well 3 (data not shown). F: Reproducibility of IgH copy number (log scale), showing mean and standard deviation of results obtained on the same sample
run in triplicate in the same run. Variability tends to increase at lower copy numbers. BMD indicates bone marrow at diagnosis.
A
B
C
E
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Figure 4. Comparison of calculated results of real-time PCR analysis on samples with known tumor contamination. A: Amplification plots on doubling dilutions
of DHL-16 DNA into normal PBL DNA. The first sample in the experiment has a DHL16 cell contamination of 6%, whereas in the last sample, tumor conta-
mination is 0.1%. B: Results of triplicate estimations for each dilution. Calculated values were derived from the amplification shown in A. Standard deviations of
triplicate experiments are shown. C: Ten-fold dilutions of DHL-16 cells into normal PBL cells were analyzed by real-time PCR and the results compared with
predicted values. Results shown are means and standard deviations of triplicate analysis. 
A
B
C
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tumor contamination. Six 10-fold dilutions of DHL-16 cells
in normal PBL cells were pre p a red, starting from 100% tumor
contamination. Real-time PCR was perf o rmed, and the
results were corrected for GAPDH copy number. Estimated
values were then compared with the mean calculated values
f rom quantitative analyses of these samples. As shown in
Figure 4C, there is a close correlation between expected and
o b s e rved values over the entire range of samples analyzed,
and all values are within 0.4 log of the estimated value. Of
note, the coefficient of variation was highest for the sample
containing 0.01% tumor contamination. 
To determine the accuracy of this technique using
patient MM samples, we perf o rmed dilution experiments
using 3 BM samples obtained at diagnosis rather than using
cell lines. All samples had greater than 20% involvement at
diagnosis. Seven series of doubling dilutions were pre p a re d
and amplified in real-time PCR. Ct values from these sam-
ples were then plotted as usual against plasmid dilutions, and
the results were corrected for GAPDH copy number. Quan-
titative data were then compared with the estimated amount
of MM cells in each of these samples. We again observed a
close relationship between theoretical and calculated values.
D i ff e rences of less than 0.05 log were observed for all the
dilution samples (data not shown). Diff e rences of less than
0.05 log are consistent with the specifications of the ABI
Prism 7700 and are in keeping with our finding in the cell
line experiments that we were able to discriminate 2-fold dif-
f e rences for samples containing more than 50 target copies.
DISCUSSION
In the present study, we examined the feasibility of quan-
titative assessment of MRD in patients with MM using IgH
re a rrangements as targets for real-time PCR with family-
specific consensus probes. By aligning IgH sequences
obtained from patients with MM, we were able to constru c t
a limited number of family-specific FR probes that allowed
successful quantitation of tumor samples by real-time PCR
in 100% of patients. Although 10 probes were used in this
study and were extremely useful to understand the
re l a t i o nship between mismatches and probe eff e c t i v e n e s s ,
only 6  p robes (M-VH1, M-VH2, L-VH3, M-VH3,
M-VH4, and L-VH5) were re q u i red to perf o rm eff e c t i v e
real-time PCR for the whole panel. For a given patient, only
the single probe that is consensus to that specific re a rr a n g e-
ment is re q u i red. The use of such consensus probes rather
than patient-specific probes greatly reduces the cost of quan-
t i t ation of MRD assessment in MM. We demonstrated a
s e n s itivity of at least 10– 4 in 26 (90%) of the entire panel of
29 patients. Short amplicons resulted in more sensitive and
e ffective amplifications, which are re q u i red to assess MRD at
the time of and after SCT in patients with MM. This study
demonstrates that real-time PCR using consensus probes is
e ffective and accurate over a wide range of tumor contamina-
tion and is re p roducible when replicate analysis is perf o rm e d
within the same experiment or on diff e rent occasions.
Real-time quantitative PCR using the TaqMan technol-
ogy re p resents a major advance for quantitative evaluation of
MRD. Several groups have addressed the feasibility of this
method using clonal markers derived from tumor- s p e c i f i c
translocations {eg, t(14:18) [31], t(9:22) [32], and t(8:21)
[33]}, with promising results. Only 2 small studies have pre-
viously investigated the use of real-time PCR using the IgH
re a rrangement as clonal markers [34,35]. The authors
showed that clonal IgH re a rrangements from patients with
MM and ALL could be successfully targeted with a re a l - t i m e
PCR-based approach. In addition, the MM study showed
that dilutions of cloned IgH re a rrangements can be re l i a b l y
used as quantitation standards, thus avoiding the need for
dilutions of patient tumor cells, which are difficult to obtain
in satisfactory amounts and with reasonable purity from ro u-
tine BM samples [34]. The limitation of these approaches is
that they re q u i re design of patient-specific probes. The use
of FR3 primers for PCR amplification does not allow suffi-
cient conserved sequences to design consensus probes. The
high cost (more than $400) of each patient-specific pro b e
s e v e rely limits such an approach for clinical studies involving
l a rge numbers of patients. In the present study, consensus
primers derived from the leader and FR1 region were used
for amplification and sequencing of IgH re a rr a n g e m e n t s .
This allowed sequencing of a larger portion of the tumor
IgH (~350 bp), including some highly conserved portions of
FR2 and FR3. We used this information to design a panel of
VH family–specific consensus probes that were used in asso-
ciation with CDR3-derived ASO primers for quantitative
analysis of clonal IgH re a rrangements. The use of consensus
p robes allows a cost-effective TaqMan-based approach for
MRD analysis using the IgH genes. It is also likely that
p robes designed for MM can be employed for MRD studies
in patients with other diff e rentiated B-cell tumors, furt h e r
reducing the overall cost of real-time PCR.
Our data show that the FR3/ASO strategy, which is
characterized by short amplicons, is more successful than
the FR1/ASO strategy, and we recommend its use when
possible. This is in keeping with the recommendations for
the use of TaqMan technology [27,28]. Of note, in a minor-
ity of patients, we were forced to select a consensus probe
derived from the FR2, and thus only the FR1/ASO strategy
could be used. However, it is conceivable that by aligning a
l a rger number of VH3 IgH re a rrangements from MM
patients, a limited number of additional FR3-derived probes
might allow successful real-time PCR using the FR3/ASO
strategy in 100% of patients. A similar approach would
probably ensure more homogeneous results if a comparison
between quantitative data from diff e rent patients was
required. We have shown that at least in some patients, the
use of consensus primers can introduce a potential bias in
quantitative results, making it difficult to compare data
obtained with different strategies. This is probably a result
of diff e rences in amplification efficiency between the plasmid
IgH sequence, which has a 100% match with the consensus
p r i m e r, and the patient IgH sequence, which can possibly
harbor several mismatches. Such bias can be avoided by
designing 2 fully matched patient-specific primers, even
when longer amplicons are required.
The problem that had to be overcome in MM as well as
in germinal center and postgerminal center B-cell malignan-
cies was that of mismatches between patient sequences and
consensus probes introduced by somatic hyperm u t a t i o n .
When we perf o rmed real-time PCR in samples from MM
patients using probes designed for ALL patients [39], we
o b s e rved a statistically significant relationship between pro b e
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e ffectiveness and number of mismatches. Three or more mis-
matches were never successful for real-time PCR, w h e reas 1
mismatch was acceptable. In the presence of 2 m i s m a t c h e s ,
real-time PCR was usually successful if the mismatches did
not disrupt 2 strong interactions. Understanding the re l a t i o n-
ship between mismatches and probe effectiveness allowed us
to design consensus probes that proved successful in 100% of
patients. Although we designed our probes using a re l a t i v e l y
l a rge number of sequences, it is conceivable that by incre a s i n g
the number of known sequences, a small number of patients
will fail real-time amplification with this panel of probes. In
p a rt i c u l a r, as was necessary for the large VH3 family, it is pos-
sible that a second probe will be re q u i red for other families,
especially for the VH4 and VH1, which include a re l a t i v e l y
l a rge number of genes and are frequently used in MM clonal
re a rrangements [41]. However, comparison of the probe with
a patient’s IgH sequence allows determination of whether a
p robe will be successful for quantitation using this approach. 
One possible approach to increase a probe’s success is to
increase the length of the probe. However, the length of the
areas of consensus within the framework regions are short,
and in mature B-cell malignancies with somatic hypermuta-
tion, it generally is not possible to increase the length of the
p robe without also increasing the number of mismatches.
The use of degenerate consensus probes and the use of
SYBR green real-time PCR (PE Biosystems), which does
not require sequence-specific probes, are possible alternative
strategies that we are currently investigating. 
This study and previous studies indicate that re a l - t i m e
PCR is less sensitive than the oligonucleotide hybridization
and nested PCR procedures that are routinely used for qual-
itative assessment of MRD [6,9,14,15]. This lower sensitiv-
ity can be explained mostly by the fact that real-time PCR is
a single-ampli fication pro c e d u re that employs lower
amounts of target DNA than standard qualitative pro c e-
dures. One potential approach to increase the sensitivity of
real-time PCR in MM involves the use of cDNA instead of
genomic DNA as a template for quantitative analysis; this
has been done previously in qualitative studies [6,9]. Some
preliminary data (not shown) support this hypothesis. How-
ever, a major concern with the use of cDNA for quantitative
analysis is that the amount of IgH cDNA may be influenced
by factors other than tumor burden, most notably the differ-
entiation level of tumor cells or treatment that includes
steroids or other cytokines [45,46], which can introduce bias
into interpretations of results.
An alternative method of quantification involves limit-
ing dilution analysis [11,20,22,23]. The limiting dilution
method may have an advantage in individual patients in
terms of level of sensitivity, but it is much more labor-inten-
sive than real-time PCR. Moreover, because multiple reac-
tions are re q u i red for limiting dilution analysis, re a l - t i m e
PCR analysis using consensus probes may still be the most
c o s t - e ff e ctive of the 2 methods.
In conclusion, this study demonstrated that re a l - t i m e
PCR using 6 consensus probes is a widely applicable, accu-
rate, and highly reproducible technique for quantification of
MRD in MM. Although it is reasonable to hypothesize that
a quantitative approach will offer a more accurate indication
of residual disease after treatment with SCT and various
immunologic approaches, a careful and extensive study of a
large panel of patients with prolonged clinical and molecular
follow-up is needed to demonstrate the prognostic relevance
of this pro c e d u re. We are currently assessing the clinical
utility of this methodology to determine the efficacy of
immunologic purging strategies, donor lymphocyte infu-
sions, and other experimental treatment approaches in
patients with MM who are undergoing SCT at our center.
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